Cargando...
Targeting adenosine for cancer immunotherapy
Immune checkpoint antagonists (CTLA-4 and PD-1/PD-L1) and CAR T-cell therapies generate unparalleled durable responses in several cancers and have firmly established immunotherapy as a new pillar of cancer therapy. To extend the impact of immunotherapy to more patients and a broader range of cancers...
Gardado en:
| Publicado en: | J Immunother Cancer |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BioMed Central
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6006764/ https://ncbi.nlm.nih.gov/pubmed/29914571 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0360-8 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|